Next 10 |
home / stock / rhhby / rhhby news
2024-07-02 11:20:47 ET Summary This article will outline nine steps I use to identify the most promising pharmaceutical companies and avoid investment pitfalls. In addition, each of the nine steps will provide examples of various factors and how they influence the assessment of th...
2024-07-01 11:07:23 ET Summary Ocugen's most advanced product candidate, OCU400, has started Phase 3 clinical trials, aiming for regulatory approval in the U.S. and Europe by 2026. The gene therapy platform shows promise in treating retinal diseases, with potential to become a mar...
2024-06-26 14:05:02 ET Summary Greenwich LifeSciences, Inc. approaches enrollment completion for the phase 3 Flamingo-01 study, using GLSI-100 for the treatment of patients with HER2/neu positive breast cancer, with full enrollment expected by the end of 2024. A prior phase 2b stu...
2024-06-26 09:10:26 ET More on Sarepta Therapeutics Sarepta Therapeutics: Pushing The Edge And Creating The Horizon Sarepta Therapeutics: Why Today's Rally On DMD Drug Label Expansion Won't Last Sarepta Therapeutics: Navigating Elevidys Upside Potential Trend...
2024-06-25 17:50:06 ET Summary Roche Holding AG stock has seen a 13% price rise in the past month following positive trial results for its obesity treatment. Weight management and associated diseases like diabetes have huge potential, as seen from the examples of Novo Nordisk and ...
2024-06-23 14:00:00 ET More on Eli Lilly, Novo Nordisk Eli Lilly: The Party Is Probably Nearing The End Novo Nordisk: Leading The Fight Against Diabetes And Obesity SA Asks: Who will launch the next big weight-loss drug? SA Asks: Is Eli Lilly or Novo No...
2024-06-21 15:33:43 ET More on Roche Holding More Of The Same Isn't Good Enough For Roche Roche Is Joining The Obesity Party But Questions Remain Emerging Leaders: Roche And Viking Therapeutics In The Obesity Treatment Race Roche inks licensing pact with Asci...
2024-06-20 17:31:25 ET More on Sarepta Therapeutics Sarepta Therapeutics: Navigating Elevidys Upside Potential Sarepta Therapeutics, Inc. (SRPT) Q1 2024 Earnings Call Transcript Sarepta Therapeutics: Growth Trajectory Alters Trading Strategy Sarepta gains aft...
2024-06-20 10:52:39 ET More on Tempest Therapeutics Tempest Therapeutics: Multiple 2024 Catalysts Make This A Must Watch Tempest Therapeutics reports Q1 results Seeking Alpha’s Quant Rating on Tempest Therapeutics Historical earnings data for Tempest T...
2024-06-20 08:45:59 ET Palm Beach, FL – June 20, 2024 – Pancreatic cancer is among the most frequently diagnosed and the seventh leading cause of cancer death globally. Pancreatic cancer becomes more common in the Western world. The prevalence rate of pancreatic adenocar...
News, Short Squeeze, Breakout and More Instantly...
Roche Holding Ltd ADR Company Name:
RHHBY Stock Symbol:
OTCMKTS Market:
Roche Holding Ltd ADR Website:
PALM BEACH, Fla., June 20, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Pancreatic cancer is among the most frequently diagnosed and the seventh leading cause of cancer death globally. Pancreatic cancer becomes more common in the Western world. The prevalence rate of panc...
Roche receives FDA clearance on its digital pathology solution for diagnostic use PR Newswire The solution, which includes the VENTANA DP 200 slide scanner, Roche's digital pathology workflow software and a display, is now cleared to aid in clinical diagnosis, enabling patho...
– The study met its primary endpoint of overall survival with a 41% reduction in the risk of death in people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated with Columvi plus chemotherapy – – This Columvi combination could provide a muc...